FKBP10 dictates RAD51 stability to drive resistance of DNA-damaging therapies in breast cancer

Despite substantial advances in targeted therapeutic regimens for breast cancer (BC), clinical management remains challenging for refractory and therapy-resistant cases, especially for molecular subtypes lacking validated actionable targets. Here, we identified that FK506-binding protein 10 (FKBP10), a peptidyl-proline isomerases, was strikingly elevated in BC tissues and potentiated the malignant behaviors of BC cells in vitro and in vivo. Besides, we discovered that FKBP10 was positively correlated with enhanced homologous recombination (HR)-mediated DNA repair and drove broad resistance to multiple DNA-damaging therapies, including cisplatin, ionizing radiation (IR) and PARP inhibitor. Mechanistically, FKBP10 physically interacted with the core HR repair protein RAD51 via a proline 22-containing motif. This interaction competitively disrupted the recognition of RAD51 by heat shock cognate 70 (HSC70), thereby protecting RAD51 from chaperone-mediated autophagy (CMA)-dependent degradation. Furthermore, FKBP10 attenuated excessive CMA flux to further stabilize RAD51 in the manner of ATF6-mediated endoplasmic reticulum stress (ERS). Importantly, we characterized a clinically actionable repurposing strategy using selumetinib, which transcriptionally repressed FKBP10 by blocking the MEK/ERK/ELK1 signaling cascade. This pharmacological intervention robustly sensitized multiple preclinical BC models to chemoradiotherapy and PARP inhibition. Collectively, our findings uncover a previously unappreciated function of FKBP10 in driving BC progression and resistance to DNA-damaging therapies, underscoring its strong potential as a tractable therapeutic target for treatment-refractory BC subsets.

Authors

Institutions

Publication Details

Journal
Cell Death and Differentiation
Published
2026-11-19
DOI
https://doi.org/10.1038/s41418-026-01927-y
Primary Topic
DNA Repair Mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FKBP10 dictates RAD51 stability to drive resistance of DNA-damaging therapies in breast cancer

Hexiang Li, Peng Hou, Zhiwei Yang, Ying Liu et al.
3 links
Cell Death and Differentiation
DNA Repair Mechanisms
article

FKBP10 dictates RAD51 stability to drive resistance of DNA-damaging therapies in breast cancer

Hexiang Li, Peng Hou, Zhiwei Yang, Ying Liu, Lihong Chen, Hongxin Cao, Jianling Wang, Yao Yao, Rui Liu, Zhen Yang, Ke Xiang
article en

Abstract

Despite substantial advances in targeted therapeutic regimens for breast cancer (BC), clinical management remains challenging for refractory and therapy-resistant cases, especially for molecular subtypes lacking validated actionable targets. Here, we identified that FK506-binding protein 10 (FKBP10), a peptidyl-proline isomerases, was strikingly elevated in BC tissues and potentiated the malignant behaviors of BC cells in vitro and in vivo. Besides, we discovered that FKBP10 was positively correlated with enhanced homologous recombination (HR)-mediated DNA repair and drove broad resistance to multiple DNA-damaging therapies, including cisplatin, ionizing radiation (IR) and PARP inhibitor. Mechanistically, FKBP10 physically interacted with the core HR repair protein RAD51 via a proline 22-containing motif. This interaction competitively disrupted the recognition of RAD51 by heat shock cognate 70 (HSC70), thereby protecting RAD51 from chaperone-mediated autophagy (CMA)-dependent degradation. Furthermore, FKBP10 attenuated excessive CMA flux to further stabilize RAD51 in the manner of ATF6-mediated endoplasmic reticulum stress (ERS). Importantly, we characterized a clinically actionable repurposing strategy using selumetinib, which transcriptionally repressed FKBP10 by blocking the MEK/ERK/ELK1 signaling cascade. This pharmacological intervention robustly sensitized multiple preclinical BC models to chemoradiotherapy and PARP inhibition. Collectively, our findings uncover a previously unappreciated function of FKBP10 in driving BC progression and resistance to DNA-damaging therapies, underscoring its strong potential as a tractable therapeutic target for treatment-refractory BC subsets.

Cell Death and Differentiation
Shaanxi Provincial People's Hospital (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Xi'an Jiaotong University (CN)
National Natural Science Foundation of China
Good health and well-being
DNA Repair Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon